Evaluation of Budoprutug (TNT119) Efficacy and Safety in Patients with Systemic Lupus Erythematosus

The primary objective of this study is to evaluate the efficacy and safety of budoprutug (TNT119) in individuals diagnosed with systemic lupus erythematosus. Determining the therapeutic effectiveness and tolerability of this agent is essential for establishing its clinical utility in managing this autoimmune condition.

The study includes a total of 13 participants diagnosed with systemic lupus erythematosus. The population consists of patients encompassing both male and female individuals. The participants fall within the 3 to 10 year age range. The sponsor did not provide information regarding selection processes, lifestyle considerations, or specific inclusion and exclusion criteria.

This Phase 3 clinical trial is designed to evaluate the efficacy and safety of budoprutug in individuals diagnosed with systemic lupus erythematosus. The study methodology utilizes a randomized, double-blind, controlled design. The clinical sequence begins with a screening visit to determine eligibility. Subsequent follow-up visits are conducted to monitor clinical outcomes and safety parameters. The protocol concludes with an end-of-study visit. Total participant involvement is determined by the specific follow-up schedule required by the protocol. Conditions leading to early termination from the study may include safety concerns or protocol non-compliance.

The assessment of efficacy in this phase 3 clinical trial focuses on the clinical manifestations of Systemic Lupus Erythematosus. Evaluation protocols are designed to monitor disease activity and therapeutic response throughout the study period.